Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093028 · ClinicalTrials.gov registry record · Phase 3
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
A Phase 3 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 3
- Development phase
- 315
- Enrollment target
NCT00093028: Completed Phase 3 study, sponsored by University of Arkansas.
NCT00093028 is a Phase 3 study that has completed, run by University of Arkansas. The registered enrollment target is 315 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093028, a Phase 3 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 315 participants
- Enrollment target
Study Summary
The purpose of this study is * to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™), * to study how many patients' myeloma responds to treatment on this study, and how many patients survive after this treatment, * to learn if a patient's genetic makeup before and after treatment can predict which patients will respond to bortezomib and Revlimid™, and to learn more about how the body responds (gene array studies).
Interventions
- DRUG bortezomib
- DRUG CC-5013 (Revlimid™)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
What the finished NCT00093028 record still lists
NCT00093028 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which bortezomib is the first listed.
NCT00093028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00093028 about?
NCT00093028 is a clinical study titled "Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II". The purpose of this study is * to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™), * to study how many patients' myeloma responds to treatment on this study, and how many patients survive after this treatment, * to learn if a patient's genetic ma...
What is the current status of trial NCT00093028?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 315 participants. The study started on 2004-01. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00093028?
The interventions under investigation include: bortezomib (DRUG), CC-5013 (Revlimid™) (DRUG).
Who is sponsoring clinical trial NCT00093028?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00093028's enrollment target sits among peer trials
315 1092nd of 2000 higher than 905 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia